These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 3479050)

  • 21. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2.
    Cano G; Milanezi F; Leitão D; Ricardo S; Brito MJ; Schmitt FC
    Diagn Cytopathol; 2003 Oct; 29(4):207-11. PubMed ID: 14506673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic and predictive factors in breast cancer].
    Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
    Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological markers in breast cancer prognosis and treatment.
    Kesisis G; Kontovinis LF; Gennatas K; Kortsaris AH
    J BUON; 2010; 15(3):447-54. PubMed ID: 20941809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma.
    Picardo AL; Diez M; Torres A; Maestro M; Ortega D; Hernando F; Gómez A; Garcia-Asenjo J; Balibrea JL
    Cancer; 1996 Mar; 77(6):1066-72. PubMed ID: 8635125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of epithelial antigens in diagnosis and staging of breast cancer].
    Artamonova EV; Tupitsyn NN; Kadagidze ZG; Letiagin VP; Ermilova VD; Ognerubov NA; Panichenko AV; Riazantseva SN
    Arkh Patol; 2002; 64(6):13-5. PubMed ID: 12534220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumor markers in breast cancer (review).
    Jotti GS; Bombardieri E
    Anticancer Res; 1990; 10(1):253-8. PubMed ID: 2185687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA, and CA 15.3: fact or fiction?
    Dixon AR; Jönrup I; Jackson L; Chan SY; Badley RA; Blamey RW
    Dis Markers; 1991; 9(3-4):167-74. PubMed ID: 1813208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tumor markers in gastrointestinal cancer and its clinical significance].
    Taguchi T; Ota J; Sumida S; Rii M
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3004-9. PubMed ID: 3479051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early diagnosis of breast cancer dissemination by tumor markers follow-up and method of prediction.
    Nekulová M; Simícková M; Pecen L; Eben K; Vermousek I; Stratil P; Cernoch M; Lang B
    Neoplasma; 1994; 41(2):113-8. PubMed ID: 8208314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
    Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.
    Nakata B; Takashima T; Ogawa Y; Ishikawa T; Hirakawa K
    Br J Cancer; 2004 Aug; 91(5):873-8. PubMed ID: 15280913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical markers as predictive tools for breast cancer.
    Walker RA
    J Clin Pathol; 2008 Jun; 61(6):689-96. PubMed ID: 18037665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Markers in breast cancer.
    Sulitzeanu D
    Isr J Med Sci; 1981; 17(9-10):865-8. PubMed ID: 7309474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [CA 15.3, a marker of breast cancer].
    Ruibal A
    Med Clin (Barc); 1988 Sep; 91(9):341-3. PubMed ID: 3216756
    [No Abstract]   [Full Text] [Related]  

  • 37. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer].
    Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H
    Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How can treatment response be measured in breast cancer patients?
    van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB
    Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Human breast cancer markers].
    Remennik LV
    Eksp Onkol; 1985; 7(4):3-8. PubMed ID: 2994992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steroid hormone receptors in the management of human breast cancer.
    Knight WA; Osborne CK; Yochmowitz MG; McGuire WL
    Ann Clin Res; 1980 Oct; 12(5):202-7. PubMed ID: 7015982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.